drugset / Trial / NCT00329095

An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance

NCT00329095

Phase 4 Completed 60 enrolled Robin, Alan L., M.D.
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Timeline

Start
2005-12
Primary completion
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified Topical
Subject Latanoprost Small molecule Topical
Subject Travoprost Other / unclassified Topical